This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frascella, E. Articles by Rosolen, A. Search for Related Content PubMed PubMed Citation Articles by Frascella, E. Articles by Rosolen, A.

American Journal of Pathology, Vol 152, 577-583, Copyright © 1998 by American Society for Investigative Pathology

REGULAR ARTICLES

Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction

E Frascella and A Rosolen
Department of Pediatrics, University of Padova, Italy.

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood. Diagnosis of RMS can be difficult when it appears as a small round-cell tumor without evidence of differentiation. Recently, a set of regulatory proteins expressed during skeletal muscle development has been described. Among them, MyoD1 has been detected by Northern blot and immunohistochemical analyses in normal skeletal muscle and RMS. Given the relevance of this marker in the diagnosis of RMS, we developed an assay to evaluate the expression of MyoD1 mRNA in small tissue specimens by reverse transcription polymerase chain reaction. Specificity and sensitivity of the assay was determined in a series of 25 tumor cell lines and 39 pediatric tumor samples, including 35 RMSs. Subsequently, we studied the expression of MyoD1 in bone marrow and peripheral blood stem cell specimens. We detected the MyoD1 transcript in normal skeletal muscle and in almost all RMSs, whereas no expression was found in non-RMS samples or in normal hematopoietic tissues. This assay showed high sensitivity and specificity, and it could be a useful molecular tool for the diagnosis of RMS within small roundcell tumors of childhood and for the detection of minimal bone marrow and peripheral blood stem cell involvement in children with RMS, regardless of the histological subtype.

This article has been cited by other articles:

				R. Saab, J. L. Bills, A. P. Miceli, C. M. Anderson, J. D. Khoury, D. W. Fry, F. Navid, P. J. Houghton, and S. X. Skapek Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells Mol. Cancer Ther., May 1, 2006; 5(5): 1299 - 1308. [Abstract] [Full Text] [PDF]

				N J Sebire and M Malone Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas J. Clin. Pathol., June 1, 2003; 56(6): 412 - 416. [Abstract] [Full Text] [PDF]

				T. Adell, A. Gómez-Cuadrado, A. Skoudy, O. S. Pettengill, D. S. Longnecker, and F. X. Real Role of the Basic Helix-Loop-Helix Transcription Factor p48 in the Differentiation Phenotype of Exocrine Pancreas Cancer Cells Cell Growth Differ., March 1, 2000; 11(3): 137 - 147. [Abstract] [Full Text]

				S. Gattenloehner, B. Dockhorn-Dworniczak, I. Leuschner, A. Vincent, H.-K. Müller-Hermelink, and A. Marx A Comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues: Implications for the Molecular Diagnosis of Minimal Disease in Rhabdomyosarcomas J. Mol. Diagn., November 1, 1999; 1(1): 23 - 31. [Abstract] [Full Text]